ABCA1 and Tangier disease: GSL biosynthesis inhibitor therapies (miglustat, eliglustat, and so on), may be particularly effective as it has been previously demonstrated that GSL accumulation can further inhibit ABCA1 expression, and in this way may have increased efficacy in Tangier disease patients.11